Observational studyBMC cancer2026
Immune checkpoint inhibitor in third-line treatment of microsatellite stable metastatic colorectal cancer: an observational and retrospective study.
Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe third-line treatment options recommended by guidelines for metastatic colorectal cancer (mCRC) are limited with unsatisfactory efficacy. Immune checkpoint inhibitor (ICI)-based strategies have been extensively explored for microsatellite stable (MSS) mCRC at third-line and above settings. This study aimed to evaluate the efficacy and safety of ICI versus non-ICI-based treatments for MSS mCRC patients in third-line setting.
methodsElectronic medical records of MSS mCRC patients who received at least third-line therapies at Renmin Hospital of Wuhan University between September 2019 and April 2024 were reviewed retrospectively. Propensity score matching (PSM) was used to balance potential confounding factors. The primary outcomes of interest were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR) and adverse events (TRAEs).
resultsOf 243 eligible patients, 93 received third-line ICI therapy and 150 treated with non-ICI therapy. The ORR were 12.9% vs 9.3% and DCR were 80.6% vs 72.0%, respectively. After PSM, an improved median PFS was exhibited in the ICI cohort (5.0 vs 3.6 months; HR = 0.55; 95% CI, 0.39–0.78; P < 0.001), with a directional improvement of OS (13.8 vs 12.4 months; HR = 0.70; 95% CI, 0.47–1.05; P = 0.086). In addition, a more significant survival benefit was found in the triplet regimen of ICI, chemotherapy and target therapy, with a median PFS of 8.2 months and OS of 20.2 months. Patients > 60 years of age, male, with liver metastasis, prior anti-VEGF(R) therapy, and wild-type RAS/BRAF could obtain PFS benefit from third-line ICI over non-ICI treatment. Thirty-six (38.7%) patients developed at least once cross-line immunotherapy in ICI cohort, resulting a directional OS improvement. Grade ≥ 3 AEs occurred in 39.8% and 43.3% of patients in each cohort. Immune-related AEs (irAEs) was 38.7%, and grade ≥ 3 irAEs was 14.0% in ICI cohort.
conclusionICI is a beneficial addition to third-line treatment for some MSS mCRC patients, providing improved survival benefit and controllable safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.